CompletedNCT04827901
Studying XEN1101 as a treatment for major depression
About this title
Read the official source — NCT04827901Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- New York and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 19, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 44
- Sponsor
- James Murrough
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04827901
- Official title
Show the full official title
A Proof of Concept Randomized Controlled Trial of XEN1101 for the Treatment of Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York · Houston
About the molecule
When a study medicine is clearly identified, HopeStage adds a short explanation of what that molecule is and links back to reliable public sources.
Azetukalner
an experimental Kv7 potassium-channel opener
targets Kv7 potassium channels
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is James Murrough.
Did this study involve medication?
Yes. The study involved medication, including XEN1101 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
